

Drugs-Real World Outcomes Appendices

Title: Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Running head: First-line ibrutinib real-world effectiveness in CLL

Authors: Philip Lee, PharmD¹; Kristin D. Kistler, PhD²; Luc Douyon, MS²; Raisa Volodarsky, PharmD, RPh¹; Alex Young, PharmD¹; Sudeep Karve, PhD³; Swetha Challagulla, MS¹

Affiliations: ¹Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA; ²Xcenda, Carrollton, TX, USA; ³AbbVie, North Chicago, IL, USA

Online Resource Table 1. Search strategy for MEDLINE, EMBASE (via Embase.com), and specific conferences

Database	MEDLINE, EMBASE (via Embase.com), and Conferences (SOHO, AVAHO, iwCLL, NCCN, AMCP and AMCP Nexus)	
Date of search	June 25, 2020	
Search	Query	Number of records found ^a
#1	'chronic lymphatic leukemia'/exp OR 'chronic lymphatic leukemia' OR 'chronic lymphocytic leukemia':ab,ti OR 'chronic lymphocytic leukaemia':ab,ti OR cll:ab,ti OR 'small lymphocytic leukemia'/exp OR 'small lymphocytic leukemia' OR 'small lymphocytic leukemia':ab,ti OR 'small lymphocytic leukaemia':ab,ti	53,573
#2	'ibrutinib'/exp OR ibrutinib:ab,ti	6,609
#3	#1 AND #2	3,597
#4	'family study'/exp OR 'family study' OR 'cohort analysis'/exp OR 'cohort analysis' OR 'longitudinal study'/exp OR 'longitudinal study' OR (('prospective study'/exp OR 'prospective study') NOT ('randomized controlled trial'/exp OR 'randomized controlled trial')) OR 'retrospective study'/exp OR 'retrospective study' OR 'follow up'/exp OR 'follow up' OR 'cross-sectional study'/exp OR 'cross-sectional study' OR 'case control study'/exp OR 'case control study' OR cohort*:ab,ti OR database*:ab,ti OR registry:ab,ti OR registries:ab,ti OR prospective:ab,ti OR retrospective:ab,ti OR 'chart review*':ab,ti OR claims:ab,ti OR survey:ab,ti OR 'real world':ab,ti OR 'real-world':ab,ti OR ((observational NEAR/2 study):ab,ti)	5.7m
#5	#3 AND #4	1,248
#6	#3 AND #4 AND [2014-2020]/py	1,188

AMCP Academy of Managed Care Pharmacy, AVAHO Association of Veteran Affairs Hematology/Oncology, Exp

explode, iwCLL International Workshop on Chronic Lymphocytic Leukemia, lim limit, NCCN National

Comprehensive Cancer Network, py publication years, SOHO Society of Hematologic Oncology, ti,ab title, abstract

^a The search strategy with the term ‘small lymphocytic lymphoma’ generated an additional 6 publications that were not relevant to the current SLR.

Online Resource Table 2. SLR inclusion and exclusion criteria

Population	Adult (≥ 18 years old) patients with CLL/SLL	• Non-human studies • <18-year-old patients • Individuals without CLL/SLL
Interventions	Ibrutinib	No ibrutinib exposure
Comparators	Any/all/no comparators	None
Outcomes	• Demographic and clinical characteristics • Clinical effectiveness • Safety • Patient-reported outcomes	Outcomes not specified in the Inclusion column
Study design	• Real-world observational studies (eg, prospective and retrospective, surveys, cross-sectional studies) • SLRs and/or meta-analyses (for reference checking)	• Interventional studies • Non-systematic reviews • Case reports • Case series (n<10) • Animal studies • Letters • Editorials
Timeframe	January 1, 2014 to June 30, 2020	≤ 2013; $> \text{June } 30, 2020$

CLL/SLL chronic lymphocytic leukemia/small lymphocytic lymphoma, *SLR* systematic literature review

Online Resource Fig. 1.

